Analysis of the Value of Sacubitril Valsartan Sodium Combined with Meto-proprool Succinate in the Treatment of Heart Failure
Objective To analyze the application value of the combination therapy of sacubitril valsartan sodium and metoprolol succinate in the treatment of heart failure.Methods 80 patients with chronic heart failure who were treated at Huimin County People's Hospital from January 2021 to June 2023 were selected as the research subjects,and they were randomly divided into two groups using blind selection method.The control group(40 cases)received treatment with sacubitril valsartan sodium,while the observation group(40 cases)received additional treatment with metoprolol succinate in addition to the control group.The levels of left ventricular ejection fraction(LVEF),B-type natriuretic peptide(BNP),6-minute walk test(6MWT),and inflammatory factors between two groups were compared.Results Af-ter treatment,the LVEF,BNP,and 6MWT cardiac function indicators of the observation group were better than those of the control group,and the differences were statistically significant(all P<0.05).The levels of interleukin-6,hyper-sensitive C-reactive protein in observation group were lower than those in the control group,and the differences were statistically significant(t=16.614,17.966,13.423,all P<0.001).Conclusion The combination therapy of sacubitril val-sartan sodium and metoprolol succinate has significant value in the treatment of heart failure patients.
NETL
NSTL
万方数据
